Literature DB >> 17202433

Are plasma citrulline and glutamine biomarkers of intestinal absorptive function in patients with short bowel syndrome?

Menghua Luo1, Concepción Fernández-Estívariz, Amita K Manatunga, Niloofar Bazargan, Li H Gu, Dean P Jones, Jan-Michael Klapproth, Shanthi V Sitaraman, Lorraine M Leader, John R Galloway, Thomas R Ziegler.   

Abstract

Sensitive biomarkers for intestinal absorptive function would be clinically useful in short bowel syndrome (SBS). Citrulline (Cit) is a product of the metabolism of glutamine (Gln) and derived amino acids by enterocytes. Cit is produced almost exclusively by the gut, which is also a major site of Gln metabolism. The goals of this study were to examine whether plasma Cit and Gln concentrations are biomarkers of residual small intestinal length and nutrient absorptive functions in adult SBS patients followed prospectively. We studied 24 stable adults with severe SBS receiving chronic parenteral nutrition (PN) in a double-blind, randomized trial of individualized dietary modification +/- recombinant human growth hormone (GH). During a baseline week, intestinal absorption studies (% absorption of fluid, kcal, nitrogen, fat, carbohydrate, sodium, phosphorus, and magnesium) were performed and concomitant plasma Cit and Gln concentrations determined. Individualized dietary modification and treatment with subcutaneous injection of placebo (n = 9) or GH (0.1 mg/kg daily x 21 days, then 3 times/week; n = 15) were then begun. PN weaning was initiated after week 4 and continued as tolerated for 24 weeks. Repeat plasma amino acid determination and nutrient absorption studies were performed at weeks 4 and 12. Residual small bowel length at baseline was positively correlated with baseline plasma Cit (r = 0.467; p = .028). However, no significant correlations between absolute Cit or Gln concentrations and the percent absorption of nutrient substrates at any time point were observed. Similarly, no correlation between the change in Cit or GLN concentration and the change in % nutrient absorption was observed (baseline vs weeks 4 and 12, respectively). By weeks 12 and 24, 7 and 13 subjects were weaned completely from PN, respectively. However, baseline plasma Cit or Gln did not predict PN weaning at these time points. We concluded that plasma Cit (but not Gln) concentrations appeared to be an indicator of small intestinal length in adult SBS. However, neither plasma Cit nor Gln was a biomarker for intestinal absorptive function in this cohort of patients with SBS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202433     DOI: 10.1177/014860710703100101

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  12 in total

1.  Plasma citrulline as marker of bowel adaptation in children with short bowel syndrome.

Authors:  Antonella Diamanti; Fabio Panetta; Paolo Gandullia; Francesco Morini; Cristian Noto; Giuliano Torre; Antonella Lezo; Bianca Goffredo; Antonella Daniele; Manuela Gambarara
Journal:  Langenbecks Arch Surg       Date:  2011-06-01       Impact factor: 3.445

Review 2.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

3.  Plasma arginine and ornithine are the main citrulline precursors in mice infused with arginine-free diets.

Authors:  Juan C Marini; Inka Cajo Didelija; Leticia Castillo; Brendan Lee
Journal:  J Nutr       Date:  2010-06-23       Impact factor: 4.798

4.  Parenteral nutrition independence in a patient left with 25 cm of ileum and jejunum: a case report.

Authors:  Laurence Genton; Patrizia Nardo; Olivier Huber; Claude Pichard
Journal:  Obes Surg       Date:  2010-02-26       Impact factor: 4.129

5.  Prospective analysis of serum carotenoids, vitamin A, and tocopherols in adults with short bowel syndrome undergoing intestinal rehabilitation.

Authors:  Menghua Luo; Concepción F Estívariz; Rosemary L Schleicher; Niloofar Bazargan; Lorraine M Leader; John R Galloway; Thomas R Ziegler
Journal:  Nutrition       Date:  2008-12-10       Impact factor: 4.008

6.  Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.

Authors:  Palle Bekker Jeppesen
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

7.  Diagnosing malabsorption in the intensive care unit.

Authors:  Martijn B Keur; Albertus Beishuizen; Adriaan A van Bodegraven
Journal:  F1000 Med Rep       Date:  2010-01-27

8.  The relationship between fasting plasma citrulline concentration and small intestinal function in the critically ill.

Authors:  Alexis Poole; Adam Deane; Matthew Summers; Janice Fletcher; Marianne Chapman
Journal:  Crit Care       Date:  2015-01-20       Impact factor: 9.097

9.  Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.

Authors:  Douglas L Seidner; Francisca Joly; Nader N Youssef
Journal:  Clin Transl Gastroenterol       Date:  2015-06-25       Impact factor: 4.488

Review 10.  Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis.

Authors:  Konstantinos C Fragkos; Alastair Forbes
Journal:  United European Gastroenterol J       Date:  2017-10-12       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.